Obesity (BMI ≥30): How to Prep for Your First Visit

Why Your First Obesity Medicine Visit Is Different From a Routine Check-Up

Obesity medicine is a board-certified specialty, and the first consultation follows a structured medical model, not a diet-coaching session. The clinician will stage your obesity, screen for at least a dozen comorbidities, and match you to a treatment tier based on your BMI, labs, and medication history.

Coming prepared means the visit moves faster and produces a concrete plan rather than a referral to come back with paperwork.

What "Staging" Means in Practice

The 2023 Obesity Medicine Association Clinical Practice Guidelines use the Edmonton Obesity Staging System (EOSS), which scores obesity from stage 0 (no risk factors, no symptoms) to stage 4 (severe end-organ damage). [1] EOSS stage, not BMI alone, drives treatment intensity. A person with a BMI of 31 and controlled type 2 diabetes is EOSS stage 2 and typically qualifies for pharmacotherapy on visit one.

The Regulatory Framework You Are Walking Into

The FDA defines two eligibility thresholds for weight-loss medications: BMI ≥30 with no comorbidities, or BMI ≥27 with at least one weight-related condition such as hypertension, dyslipidemia, type 2 diabetes, or obstructive sleep apnea. [2] Your clinician will confirm you meet one of these before prescribing. Documenting your comorbidities in advance, with dates of diagnosis and current treatments, removes a step.

The Documents and Data to Bring

Your Medication List

Bring every prescription, over-the-counter drug, and supplement you take, including doses and frequency. Several obesity medications have drug interactions that change prescribing decisions on the spot. Naltrexone-bupropion ER (Contrave) is contraindicated with opioids and requires a seizure-risk review. Phentermine-topiramate ER (Qsymia) is contraindicated with monoamine oxidase inhibitors. [3] Semaglutide 2.4 mg (Wegovy) and tirzepatide 15 mg (Zepbound) slow gastric emptying, which may lower oral contraceptive absorption. [4]

Recent Labs (Within the Past 12 Months)

Pull and bring any lab results you have. The standard obesity workup includes:

• Fasting plasma glucose and HbA1c (screens for prediabetes and type 2 diabetes)
• Full lipid panel with LDL, HDL, non-HDL, and triglycerides
• Thyroid-stimulating hormone (TSH) to rule out hypothyroidism as a contributing factor
• Comprehensive metabolic panel (CMP) for liver and kidney function
• Complete blood count (CBC)
• Uric acid if gout is suspected

The Endocrine Society's 2015 obesity management guideline recommends screening all patients with obesity for these metabolic abnormalities at baseline. [5] If you arrive without labs, most telehealth and clinic-based practices will order a panel at the first visit, but a second appointment may then be needed before prescribing begins.

A 3-Day Diet Record

Write down everything you ate and drank over the past three days, including rough portion sizes and the time of day. You do not need a calorie-tracking app. A handwritten list is enough. This record lets the clinician or registered dietitian assess meal timing, ultra-processed food load, protein intake, and liquid calorie sources without spending 20 minutes asking you to recall meals during the visit itself.

Sleep and Blood Pressure History

Undiagnosed obstructive sleep apnea (OSA) is present in roughly 30-50% of adults with obesity. [6] If you have ever been told you snore loudly, or if you wake unrefreshed despite 7-8 hours in bed, note this. Some obesity medications, particularly phentermine-containing products, require cleared OSA before use because of cardiovascular stimulant effects. Bring your blood pressure readings from the past 3-6 months if you have them; hypertension affects which medications are preferred.

How to Understand Your BMI and What the Clinician Will Calculate

BMI equals weight in kilograms divided by height in meters squared. At the visit, the clinician will also measure waist circumference. A waist circumference above 88 cm (35 inches) in women or above 102 cm (40 inches) in men independently raises cardiometabolic risk even when BMI is in the borderline range. [7]

Body Composition Beyond BMI

BMI has well-documented limits as a sole metric. A 2016 analysis published in the International Journal of Obesity found that 29.2 million Americans with BMI in the normal range (18.5-24.9) had cardiometabolic abnormalities, while some individuals classified as obese by BMI were metabolically healthy. [8] Your clinician may use bioelectrical impedance or DEXA scan data if available, but for initial visit purposes, BMI plus waist circumference plus metabolic labs is the practical standard.

The Edmonton Obesity Staging System Score

Ask your clinician to tell you your EOSS score at the end of the visit. Stage 0-1 typically starts with intensive behavioral therapy and considers medication if 3-6 months of lifestyle changes do not produce at least 5% weight loss. Stage 2-3 usually proceeds directly to pharmacotherapy or combined therapy. Stage 4, which involves severe organ failure, may require bariatric surgery referral. [1]

FDA-Approved Medications Your Clinician May Discuss

GLP-1 Receptor Agonists: Semaglutide and Liraglutide

Semaglutide 2.4 mg subcutaneous injection once weekly (Wegovy) is currently the most-prescribed GLP-1 agent for obesity. In STEP-1 (N=1,961), participants treated with semaglutide 2.4 mg lost a mean of 14.9% of body weight at 68 weeks compared with 2.4% in the placebo group (P<0.001). [9] The SELECT trial (N=17,604) further showed a 20% reduction in major adverse cardiovascular events in adults with obesity and established cardiovascular disease. [10]

Liraglutide 3.0 mg (Saxenda) is an older daily injectable GLP-1 agonist. SCALE Obesity (N=3,731) showed 8.0% mean weight loss at 56 weeks versus 2.6% with placebo. [11] It remains an option when weekly injections are preferred to be avoided or when cost is a factor.

GIP/GLP-1 Dual Agonist: Tirzepatide

Tirzepatide (Zepbound), approved by the FDA in November 2023 for chronic weight management, targets both GLP-1 and GIP receptors. In SURMOUNT-1 (N=2,539), the 15 mg dose produced a mean weight loss of 20.9% at 72 weeks versus 3.1% with placebo (P<0.001). [12] This is the largest mean weight reduction seen in any phase 3 pharmacotherapy trial to date. Tirzepatide's SURMOUNT-2 trial specifically studied adults with obesity and type 2 diabetes, showing 15.7% weight loss at 72 weeks with the 15 mg dose. [13]

Older Agents Still in Use

Phentermine-topiramate ER (Qsymia) produced 9.8% mean weight loss at 56 weeks in the CONQUER trial (N=2,487) at the top dose (15 mg/92 mg). [14] Naltrexone-bupropion ER (Contrave) produced 6.4% weight loss at 56 weeks in the COR-I trial (N=1,742). [15] Orlistat 120 mg three times daily (Xenical) is the only agent that works via fat malabsorption rather than CNS or incretin effects; it reduces fat absorption by roughly 30% and typically produces 3-5% weight loss.

What the Clinician Will Ask You, and Why

The visit will include a structured history covering several domains. Preparing answers to these questions in advance saves significant time.

Weight History

Be ready to describe your highest adult weight, your lowest adult weight since age 21, and any periods of significant gain or loss with approximate dates and causes. Clinicians use this to distinguish primary obesity from secondary causes such as hypothyroidism, Cushing syndrome, or medication-induced weight gain (common with antipsychotics, insulin, and some antidepressants).

Previous Weight-Loss Attempts

List every structured attempt: commercial programs (Weight Watchers, Jenny Craig), very-low-calorie diets, prior prescription medications (including doses and whether you stopped due to side effects or lack of response), and any bariatric procedures. The 2023 OMA guidelines recommend that prior medication failure does not preclude trying a different agent; mechanism class matters. [1] Someone who lost <5% on orlistat may lose 15-20% on a GLP-1 receptor agonist.

Mental Health Screening

Obesity and depression co-occur at rates roughly double the general population rate. The Obesity Medicine Association and the AACE both recommend a PHQ-9 screen at baseline. [1, 16] Naltrexone-bupropion ER has an FDA black-box warning for suicidality as a bupropion-containing medication, so clinicians review psychiatric history before prescribing it.

Family History

A first-degree family history of multiple endocrine neoplasia type 2 (MEN2) or medullary thyroid carcinoma (MTC) is a contraindication to all GLP-1 receptor agonists, including semaglutide and tirzepatide, per FDA prescribing information. [4] Note any family history of thyroid cancer at your visit.

Lifestyle Changes That Start Before Your First Prescription

No medication works in isolation. The 2013 AHA/ACC/TOS obesity guideline, which was updated in 2022, states that a comprehensive lifestyle intervention producing a deficit of 500-750 kcal per day forms the foundation of treatment at all stages. [17] In STEP-1, all participants received lifestyle counseling in addition to either semaglutide or placebo, which means the trial's outcomes reflect combined therapy.

Protein and Meal Timing

Increasing dietary protein to 1.2-1.6 g/kg of ideal body weight per day is associated with greater preservation of lean mass during caloric restriction. A 2012 meta-analysis in the American Journal of Clinical Nutrition (N=1,063 pooled participants) found higher-protein diets produced significantly greater fat loss while preserving fat-free mass compared with standard-protein diets. [18] Your clinician may refer you to a registered dietitian for a personalized prescription.

Physical Activity Baseline

Write down your current weekly activity: steps per day, minutes of moderate exercise, any resistance training. The USPSTF recommends offering or referring adults with a BMI ≥30 to intensive, multicomponent behavioral interventions with at least 12 to 26 sessions in the first year. [19] Physical activity alone rarely produces more than 2-3% weight loss, but it preserves muscle mass during medication-assisted weight loss and dramatically reduces cardiovascular risk independent of weight.

Understanding Informed Consent and Side Effect Profiles

Your clinician will review expected side effects before prescribing. The most common adverse effects of GLP-1 and GIP/GLP-1 medications are gastrointestinal: nausea, vomiting, diarrhea, and constipation. In STEP-1, nausea occurred in 44.2% of semaglutide participants versus 16.0% with placebo, though most cases were mild-to-moderate and resolved within the first 4-8 weeks. [9]

Dose Escalation Schedules

GLP-1 agents use slow dose escalation to reduce GI side effects. Semaglutide 2.4 mg starts at 0.25 mg weekly for 4 weeks, escalating every 4 weeks to a maintenance dose of 2.4 mg, over a 16-week titration. Tirzepatide starts at 2.5 mg weekly, escalating every 4 weeks to the target dose (5, 10, or 15 mg), over a 16-20 week period. [4, 12] Tell your clinician if you have a history of gastroparesis or severe GERD, as slower titration or a different agent may be preferred.

Monitoring After Starting Medication

Expect follow-up at 4-12 weeks after starting any obesity pharmacotherapy to assess tolerability, blood pressure, heart rate, and early weight response. The American Association of Clinical Endocrinology's 2016 Obesity Algorithm recommends assessing a 5% weight-loss response at 12 weeks as the minimum threshold for continuing the current treatment. [16] If you have not lost at least 5% at 12 weeks, the dose may be increased or the agent may be changed.

Questions to Ask Your Clinician Before Leaving

Arrive with these written down:

1. Which medication are you recommending and why, given my specific labs and history?
2. What is the expected timeline to see a 5% weight reduction?
3. What side effects should prompt me to call the office versus wait it out?
4. Will my insurance cover this medication, and what is the prior-authorization process?
5. Do I need a referral to a registered dietitian or behavioral therapist?
6. At what point would you consider bariatric surgery referral?
7. How will we monitor for medication-related changes in heart rate or thyroid function?

GLP-1 and GIP/GLP-1 medications carry a significant monthly out-of-pocket cost (often $900-1,400 without insurance coverage). Knowing the prior-authorization requirements before you leave the office prevents a gap in starting treatment.

Telehealth Versus In-Person: What Changes in the Prep

Telehealth obesity medicine visits follow the same clinical checklist but require self-reported vitals. Before a telehealth first visit, measure and record your weight on a home scale (same time of day, minimal clothing), your waist circumference with a soft tape measure, and your blood pressure with an upper-arm cuff (wrist cuffs are less accurate). [20] Most telehealth platforms will order lab work to a local Quest or LabCorp before your appointment; if not, ask during scheduling.

The FDA does not restrict GLP-1 or obesity pharmacotherapy to in-person diagnosis. Telehealth prescribing of these agents is legal in all 50 states for adults who meet BMI and comorbidity criteria, provided a valid prescriber-patient relationship is established. [2]